naltrexone has been researched along with prazosin in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (8.70) | 18.7374 |
1990's | 5 (21.74) | 18.2507 |
2000's | 7 (30.43) | 29.6817 |
2010's | 9 (39.13) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Pinnock, RD | 1 |
Kanda, A; Kimura, T; Koyanagawa, H; Musha, T; Satoh, S | 1 |
Imai, N; Kawashima, S; Liang, CS; Stone, CK; Tuttle, RR; Woolf, PD | 1 |
Miranda, HF; Naquira, D; Pinardi, G; Sierralta, F | 1 |
Intengan, HD; Smyth, DD | 2 |
Brotchie, JM; Hill, MP | 1 |
Angers, P; Dalbó, S; Jürgensen, S; Ribeiro-do-Valle, RM; Santos, AR | 1 |
Miranda, HF; Pinardi, G; Prieto, JC; Puig, MM | 1 |
Climent, L; Horga, A; Horga, JF; Peiró, AM; Zapater, P | 1 |
Froehlich, JC; Hausauer, BJ; Rasmussen, DD | 1 |
Czachowski, CL; Verplaetse, TL | 1 |
Froehlich, JC; Kincaid, CL; Rasmussen, DD | 1 |
Hackett, D; Heal, DJ; Hutson, PH; Murray, F; Vickers, SP | 1 |
Castor, MGME; Duarte, IDG; Guzzo, LS; Klein, A; Petrocchi, JA; Romero, TRL; Soares Santos, RR | 1 |
1 review(s) available for naltrexone and prazosin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for naltrexone and prazosin
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphé nucleus in vitro.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Animals; Benzofurans; Bicuculline; Bombesin; Cholecystokinin; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Evoked Potentials; Glutamates; Glutamic Acid; In Vitro Techniques; Kynurenic Acid; N-Methylaspartate; Naloxone; Naltrexone; Neurons; Picrotoxin; Prazosin; Pyrrolidines; Quinoxalines; Raphe Nuclei; Rats; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Serotonin; Synapses; Tetrodotoxin | 1992 |
Inhibition of vagal transmission by cardiac sympathetic nerve stimulation in the dog: possible involvement of opioid receptor.
Topics: Blood Pressure; Electric Stimulation; Enkephalin, Leucine; Heart; Heart Rate; Methacholine Chloride; Methacholine Compounds; Naloxone; Naltrexone; Norepinephrine; Prazosin; Receptors, Opioid; Sympathetic Nervous System; Synaptic Transmission; Vagus Nerve; Yohimbine | 1989 |
The role of endogenous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dogs.
Topics: Adrenocorticotropic Hormone; Animals; beta-Endorphin; Dogs; Endorphins; Heart Failure; Hemodynamics; Hydrocortisone; Naltrexone; Prazosin; Propranolol; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Opioid; Sympathetic Nervous System | 1987 |
alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Clonidine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intraventricular; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Prazosin; Receptors, Opioid; Yohimbine | 1996 |
Clonidine-induced increase in osmolar clearance and free water clearance via activation of two distinct alpha 2-adrenoceptor sites.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Clonidine; Male; Naltrexone; Osmolar Concentration; Prazosin; Quinoxalines; Rats; Rats, Sprague-Dawley; Water | 1996 |
Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance.
Topics: Adrenergic alpha-Agonists; Animals; Body Water; Brimonidine Tartrate; Guanfacine; Idazoxan; Kidney; Male; Naltrexone; Prazosin; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 1997 |
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzofurans; Biogenic Monoamines; Clonidine; Disease Models, Animal; Drug Combinations; Drug Synergism; Locomotion; Male; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Prazosin; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine; Yohimbine | 1999 |
Involvement of 5-HT2 receptors in the antinociceptive effect of Uncaria tomentosa.
Topics: Acetic Acid; Analgesics; Animals; Arginine; Atropine; Behavior, Animal; Capsaicin; Cat's Claw; Dose-Response Relationship, Drug; Formaldehyde; Ketanserin; Male; Mice; Motor Activity; Naltrexone; Pain; Pain Measurement; Phytotherapy; Plant Preparations; Prazosin; Receptors, Serotonin, 5-HT2; Reserpine; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Yohimbine | 2005 |
Isobolographic analysis of multimodal analgesia in an animal model of visceral acute pain.
Topics: Acetaminophen; Acute Disease; Adrenergic alpha-Antagonists; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Behavior, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Ketoprofen; Male; Mice; Morphine; Muscarinic Antagonists; Naltrexone; Narcotic Antagonists; Pain; Prazosin | 2008 |
Ketanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Analgesics; Animals; Dose-Response Relationship, Drug; Drug Synergism; Ketanserin; Male; Mice; Mice, Inbred Strains; Morphine; Naltrexone; Pain; Pain Measurement; Pain Threshold; Prazosin; Pyrrolidines; Receptors, Adrenergic, alpha-1; Receptors, Opioid, kappa; Receptors, Serotonin, 5-HT2; Serotonin Antagonists | 2011 |
Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Combinations; Drug Synergism; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Rats, Wistar; Treatment Outcome | 2013 |
Low-dose prazosin alone and in combination with propranolol or naltrexone: effects on ethanol and sucrose seeking and self-administration in the P rat.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Drug-Seeking Behavior; Ethanol; Male; Naltrexone; Narcotic Antagonists; Prazosin; Propranolol; Rats; Reinforcement, Psychology; Self Administration; Sucrose | 2015 |
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combination; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
Effects of lisdexamfetamine in a rat model of binge-eating.
Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Models, Animal; Eating; Feeding Behavior; Female; Idazoxan; Lisdexamfetamine Dimesylate; Naltrexone; Olanzapine; Prazosin; Prodrugs; Raclopride; Rats; Rats, Wistar; Rolipram | 2015 |
Noradrenaline induces peripheral antinociception by endogenous opioid release.
Topics: Analgesics; Animals; Cinnamates; Dinoprostone; Dose-Response Relationship, Drug; Hyperalgesia; Leucine; Male; Morphine Derivatives; Naltrexone; Norepinephrine; Opioid Peptides; Pain Measurement; Prazosin; Propranolol; Rats; Yohimbine | 2018 |